pSivida Corp. (NASDAQ:PSDV, ASX:PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced that it will host a live webcast and conference call Monday, November 14, 2011, at 9:00 am ET to discuss the receipt by its licensee Alimera Sciences, Inc. of a complete response letter from the U.S. Food and Drug Administration in response to the New Drug Application for ILUVIEN® for the treatment of diabetic macular edema associated with diabetic retinopathy announced earlier today.
“In addition to discussing the CRL, we will also discuss our product pipeline outside of ILUVIEN, including our other two clinical stage product candidates: one we are independently developing to treat uveitis affecting the posterior segment of the eye using the same insert as ILUVIEN and the other we are developing in collaboration with Pfizer to treat glaucoma and ocular hypertension. We also continue to advance our BioSilicon research and development,” said Dr. Paul Ashton, Ph.D., President and CEO of pSivida. “Although we will not be due the $25 million milestone payment for FDA approval of ILUVIEN, we continue to believe that our $21.3 million of cash resources at September 30, 2011 is sufficient to support our current and planned operations into at least calendar year 2013.”
The conference call may be accessed by dialing (866) 788-0538 from the U.S. and Canada, or (857) 350-1676 from international locations, passcode 53581980. The conference can also be accessed on the pSivida Corp. website at www.psivida.com. A replay of the call will be available approximately two hours following the end of the call through November 21, 2011. The replay may be accessed by dialing (888) 286-8010 within the U.S. and Canada or (617) 801-6888 from international locations, passcode 70929780.
The conference call will be available via the Internet at www.psivida.com and will also be distributed through the Thomson StreetEvents Network. Individual investors can listen to the call via www.earnings.com and Institutional investors can access the call via www.streetevents.com. Listeners are encouraged to login at least 15 minutes prior to the start of the scheduled presentation to register, download and install any necessary audio software. The call will be archived and accessible on the Web site for approximately 30 days.About pSivida Corp. pSivida Corp., headquartered in Watertown, MA, develops tiny, sustained release, drug delivery products designed to deliver drugs at a controlled and steady rate for months or years. pSivida is currently focused on treatment of chronic diseases of the back of the eye utilizing its core technology systems, Durasert(TM) and BioSilicon(TM).
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV